Showing 881-890 of 9422 results for "".
Mid-Face Filler Pearls
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/mid-face-filler-pearls/18537/Shannon Humphrey, MD shares three pearls for avoiding the filler complication patients fear the most in the mid-face: unnatural results. You must have a plan, she says, to avoid treating the cheeks as an island rather than as part of the full face.Managing Office Politics
https://practicaldermatology.com/topics/practice-management/managing-office-politics/19101/Neal Bhatia, MD, Co-Chief Medical Editor of Practical Dermatology® magazine, shares pearls for successfully understanding and navigating the scope of office politics and relationships. DermTube's coverage of the AAD's 2014 Summer Meeting is not endorsed by or affiliated with the American Academy ofEvaluating Lebrikizumab in Pigmented Skin
https://practicaldermatology.com/series/updates-atopic-dermatitis/evaluating-lebrikizumab-in-pigmented-skin/36490/Andrew Alexis, MD, MPH, discusses new data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from the phase 3b Admirable trial, the first dedicated study for evaluating the efficacy and safety of Lilly's FDA-approved medicine in adult and adolescent patients with pigmented skin andEczematous Dermatitis: Dr. Zirwas
https://practicaldermatology.com/programs/practical-dermatology/eczematous-dermatitis-dr-zirwas/32689/Matthew Zirwas, MD, talks about the therapeutic strategies for non-atopic dermatitis—particularly hand dermatitis and facial dermatitis—that he covered during "Eczematous Dermatitis Update 2025: Contact, Hand, Head and Neck, Eyelid and More" at Maui Derm 2025.Get Ready for JAK Inhibitors
https://practicaldermatology.com/topics/psoriasis/get-ready-for-jak-inhibitors/19928/JAK inhibitors are going to change the way we think about refractory disease, says Brett King, MD. He addresses the significant increase in study of these agents and the many potential uses for refractory diseases like alopecia, atopic dermatitis, vitiligo, psoriasis, and more.Developing PsA: Risk Factors for Psoriasis Patients
https://practicaldermatology.com/topics/psoriasis/developing-psa-risk-factors-for-psoriasis-patients/19651/Can patients with psoriasis lessen their chance of developing psoriatic arthritis? Ronald Prussick, MD discusses the known risk factors and the importance of weight and a low BMI for these patients. He also talks about non-alcoholic fatty liver syndrome in this patient population.Topical Toxins: Now and Later
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/topical-toxins-now-and-later/18768/Topical neurotoxins are in late-stage development, with the potential to offer "softer" results and reduction of fine wrinkles. But they may not be approved for another few years. In the meantime, micro channel delivery of toxins, such as with AquaGold, is an option. Joel Schlessinger, MD, founder oCSF After Dark
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/csf-after-dark/20386/ICYMI: Updates from behind the scenes at the 10th Annual Cosmetic Surgery Forum.Scientifically Speaking: Can We Conquer Cellulite?
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-can-we-conquer-cellulite/19872/Treating cellulite has been a challenge, but new and emerging technologies offer hope to overcome this common condition. Host Joel L. Cohen, MD talks with Nazanin Saedi, MD, Endo's Mike McLane, PhD, and Soliton's Wally Klemp.DermWire TV Extra: How ILDS Helps Dermatology Go Global
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-how-ilds-helps-dermatology-go-global/26912/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Henry Lim, MD, president of the International League of Dermatology Societies (ILDS), to discuss international developments in research and therapeutics, how ILDS helps enhance dermatologists' interactions with the specialty worl